Emerging treatments
Rituximab
In one phase 2 exploratory trial, young people (ages 12-20 years) with Graves disease were given a single dose of rituximab, a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes, as an adjunct to 12 months of antithyroid drug treatment. At 24 months, 48% (13 out of 27) of patients were in remission. No serious adverse events were linked to the treatment regimen.[151] A randomized controlled trial of rituximab in a larger group of young patients with Graves disease is required to determine safety and efficacy in this population.
Use of this content is subject to our disclaimer